Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
Public ClinicalTrials.gov record NCT01234025. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study of Docetaxel and Prednisone, With or Without ISIS 183750 (an eIF4E Inhibitor), in Patients With Castrate-Resistant Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to examine the safety, tolerability and progression-free survival of patients with Castrate-Resistant Prostate Cancer treated with ISIS EIF4E Rx in combination with docetaxel and prednisone.
Study identification
- NCT ID
- NCT01234025
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 113 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2010 (Type not available)
- Primary completion
- May 2013 (Actual)
- Completion
- Dec 2013 (Actual)
- Last update posted
- Oct 6, 2023
2010 – 2013
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| San Bernardino Urological Associates | San Bernardino | California | 92404-4816 | — |
| Fort Range Cancer Center | Fort Collins | Colorado | 80528 | — |
| Norwalk Hospital- Whittingham Cancer Center | Norwalk | Connecticut | 06850 | — |
| Lakeland Regional Cancer Center | Lakeland | Florida | 33805 | — |
| University of Miami, Miller School of Medicine - Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Central Baptist Hospital Clinical Research Center | Lexington | Kentucky | 40503 | — |
| Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center | Shreveport | Louisiana | 71103 | — |
| St. Luke's - Roosevelt Hospital Center | New York | New York | 10019 | — |
| James P. Wilmont Cancer Center - University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01234025, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2023 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01234025 live on ClinicalTrials.gov.